A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease (NCT07483073)
A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
🩺 Plain-English Summary (8th-Grade Level)
Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adults with moderately to severely active ulcerative colitis or Crohn's disease and will last at least 62 weeks.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic in Arizona - Scottsdale — Scottsdale, Arizona
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (70 Sites)
Showing the first 25 of 70 sites.
- Mayo Clinic in Arizona - Scottsdale — Scottsdale, Arizona
- Biopharma Informatic, LLC — Los Angeles, California
- Om Research LLC — Oxnard, California
- South Denver Gastroenterology — Englewood, Colorado
- Gastro Health Research - Miami — Miami, Florida
- Ezy Medical Research — Miami Lakes, Florida
- Atlanta Gastroenterology Associates - Peachtree Dunwoody — Atlanta, Georgia
- Rush University Medical Center — Chicago, Illinois
- Cotton O'Neil Digestive Health Center — Topeka, Kansas
- Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center — Wyoming, Michigan
- KAD Clinical Research — St Louis, Missouri
- Vector Clinical Trials — Las Vegas, Nevada
- One of a Kind Clinical Research Center - Kingwood — Kingwood, Texas
- Southern Star Research Institute — San Antonio, Texas
- AZ Maria Middelares — Ghent,
- UZ Gent — Ghent,
- UZ Leuven — Leuven,
- AZ Delta vzw — Roeselare,
- Loema Instituto de Pesquisa Clinica — Campinas,
- Fundação Universidade de Caxias do Sul (FUCS) — Caxias do Sul,
- Centro Digestivo de Curitiba — Curitiba,
- Centro de Pesquisa Clínica de Marília - CPCLIM — Marília,
- CPHosp Medicina, Ensino e Pesquisa (CPQuali) — São Paulo,
- CPCLIN — São Paulo,
- BR Trials - Ensaios Clinicos e Consultoria — São Paulo,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: clinical_inquiry_hub@lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colitis, Ulcerative
- A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis — Oakland, California
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Arcadia, California
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Litchfield Park, Arizona
- Determination of the Optimal Treatment Target in Ulcerative Colitis — Ypsilanti, Michigan
- A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis — Kelowna, British Columbia
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis — San Francisco, California
Explore by condition: All Colitis, Ulcerative clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.